Wilmington Savings Fund Society FSB Buys New Position in IQVIA Holdings Inc. (NYSE:IQV)

Wilmington Savings Fund Society FSB acquired a new stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 9,747 shares of the medical research company's stock, valued at approximately $2,310,000.

Several other large investors have also recently bought and sold shares of IQV. Arvest Bank Trust Division acquired a new stake in shares of IQVIA during the third quarter valued at about $21,079,000. World Investment Advisors LLC acquired a new position in shares of IQVIA in the 3rd quarter valued at about $14,633,000. Sanctuary Advisors LLC grew its position in shares of IQVIA by 60.8% during the 3rd quarter. Sanctuary Advisors LLC now owns 5,498 shares of the medical research company's stock worth $1,303,000 after buying an additional 2,079 shares during the period. Pine Valley Investments Ltd Liability Co increased its position in shares of IQVIA by 0.5% during the third quarter. Pine Valley Investments Ltd Liability Co now owns 9,481 shares of the medical research company's stock worth $2,247,000 after acquiring an additional 50 shares in the last quarter. Finally, Unigestion Holding SA purchased a new position in shares of IQVIA during the third quarter valued at approximately $521,000. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on IQV. Barclays decreased their price target on shares of IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. The Goldman Sachs Group dropped their price objective on IQVIA from $280.00 to $250.00 and set a "buy" rating for the company in a research note on Friday, November 1st. Truist Financial lowered their price target on IQVIA from $265.00 to $261.00 and set a "buy" rating on the stock in a report on Thursday. Redburn Atlantic initiated coverage on shares of IQVIA in a research report on Monday, October 14th. They issued a "buy" rating and a $276.00 price objective on the stock. Finally, JPMorgan Chase & Co. dropped their target price on shares of IQVIA from $279.00 to $240.00 and set an "overweight" rating for the company in a research report on Tuesday, November 5th. Four research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, IQVIA presently has an average rating of "Moderate Buy" and a consensus price target of $256.19.

IQVIA Price Performance

Shares of NYSE IQV traded down $1.31 during trading on Friday, hitting $199.06. 1,161,543 shares of the company were exchanged, compared to its average volume of 1,186,062. IQVIA Holdings Inc. has a 1 year low of $187.62 and a 1 year high of $261.73. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. The company has a market cap of $36.13 billion, a price-to-earnings ratio of 26.12, a PEG ratio of 2.07 and a beta of 1.49. The firm's fifty day moving average price is $212.24 and its 200 day moving average price is $224.23.

IQVIA Company Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.